Dexamethasone ophthalmic - InSite Vision
Alternative Names: Dexamethasone ophthalmic; DexaSite; ISV-305Latest Information Update: 17 Dec 2024
At a glance
- Originator InSite Vision
- Class Anti-inflammatories; Antiallergics; Antiemetics; Antihyperglycaemics; Antineoplastics; Antirheumatics; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Ketones; Non-opioid analgesics; Phosphates; Pregnadienetriols; Small molecules; Sodium compounds; Vestibular disorder therapies
- Mechanism of Action Glucocorticoid receptor agonists; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Blepharitis; Ocular inflammation; Ocular pain
Most Recent Events
- 17 Dec 2024 Discontinued - Phase-III for Blepharitis in USA (Ophthalmic) (Sun Pharmaceutical pipeline, December 2024)
- 17 Dec 2024 Discontinued - Phase-III for Ocular inflammation (In adolescents, In the elderly, In adults) in USA (Ophthalmic) (Sun Pharmaceutical pipeline, December 2024)
- 17 Dec 2024 Discontinued - Phase-III for Ocular inflammation in USA (Ophthalmic) (Sun Pharmaceutical pipeline, December 2024)